Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial

Characteristics

UK-12 h (n = 70)

UK-2 h (n = 59)

Gender (male/female)

41/29

37/22

Age mean ± SD (y)

55.1 ± 16.1

56.5 ± 14.1

Weight mean ± SD (kg)

67.7 ± 11.9

68.2 ± 10.4

BMI mean ± SD(kg/m2)

24.4 ± 4.2

24.6 ± 3.5

Prior DVT or PE, n (%)

3(4.3)

5(8.6)

CVD, n (%)

8(11.4)

7(12.1)

Hypertension, n (%)

17(24.3)

18(31.0)

Diabetes mellitus, n (%)

6(8.6)

4(6.9)

COPD, n (%)

4(5.7)

5(8.6)

Malignancy, n (%)

2(2.9)

3(5.2)

Systolic blood pressure mean ± SD (mmHg)

127.0 ± 21.0

121.8 ± 17.0

Diastolic blood pressure mean ± SD (mmHg)

80.9 ± 12.3

74.2 ± 13.9

PaO2 (mmHg)

72.9 ± 20.3

70.8 ± 16.5

PaCO2 (mmHg)

34.5 ± 5.9

33.8 ± 6.6

Respiratory rate mean ± SD (rpm)

23.1 ± 4.9

23.7 ± 6.4

Heart rate mean ± SD (bpm)

96.4 ± 17.6

93.9 ± 17.8

Hb mean ± SD (g/L)

128.9 ± 22.3

125.7 ± 20.8

Hemodynamically massive PE*, n (%)

20 (28.6)

20 (33.9)

Anatomically massive PE with RVD & PH¶, n (%)

50(71.4)

39 (66.1)

  1. * Arterial hypotension (a systolic arterial pressure <90 mm Hg or a drop in systolic arterial pressure of at least 40 mm Hg for at least 15 minutes) or cardiogenic shock.
  2. ¶ Pulmonary artery obstruction > 2 lobes on CTPA or >7 segments on V/Q scan combined with RVD and PH, but without hypotension or cardiogenic shock.